Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.

about

Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.

Item

http://www.wikidata.org/entity/Q38686396

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Looking to the future and lear ...... ions of biosimilars in cancer.

@en

type

Item

label

Looking to the future and lear ...... ions of biosimilars in cancer.

@en

prefLabel

Looking to the future and lear ...... ions of biosimilars in cancer.

@en

P1476

Looking to the future and lear ...... ions of biosimilars in cancer.

@en

P2093

Dasom Choi

http://www.w3.org/2001/XMLSchema#string

Hyuk-Chan Kwon

http://www.w3.org/2001/XMLSchema#string

Michinori Ogura

http://www.w3.org/2001/XMLSchema#string

Won Seog Kim

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets

Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.

Patient attitudes and understanding about biosimilars: an international cross-sectional survey

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

P304

17-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0154

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

15s

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28482701

http://www.w3.org/2001/XMLSchema#string